DAVID FOGELMAN to Carcinoid Tumor
This is a "connection" page, showing publications DAVID FOGELMAN has written about Carcinoid Tumor.
Connection Strength
0.224
-
Phase III study of pasireotide long-acting release in patients with metastatic neuroendocrine tumors and carcinoid symptoms refractory to available somatostatin analogues. Drug Des Devel Ther. 2015; 9:5075-86.
Score: 0.113
-
Pazopanib and depot octreotide in advanced, well-differentiated neuroendocrine tumours: a multicentre, single-group, phase 2 study. Lancet Oncol. 2015 Jun; 16(6):695-703.
Score: 0.110